2024
Cost-effectiveness of bevacizumab therapy in the care of patients with hereditary hemorrhagic telangiectasia
Wang D, Ito S, Waldron C, Butt A, Zhang E, Krumholz H, Al-Samkari H, Goshua G. Cost-effectiveness of bevacizumab therapy in the care of patients with hereditary hemorrhagic telangiectasia. Blood Advances 2024, 8: 2835-2845. PMID: 38537061, PMCID: PMC11176968, DOI: 10.1182/bloodadvances.2024012589.Peer-Reviewed Original ResearchIncremental net monetary benefitHereditary hemorrhagic telangiectasiaStandard-of-careBevacizumab therapyWillingness-to-payNet monetary benefitHemorrhagic telangiectasiaWillingness-to-pay thresholdsStandard-of-care strategiesCare of patientsCost-effectiveness analysisAnti-VEGF bevacizumabSystemic antiangiogenic therapyCurrent standard-of-careMonetary benefitsTime horizonFormulary placementHealthcare resource utilizationStandard of careLifetime time horizonPatient quality-of-lifeScenario analysisProbabilistic sensitivity analysesIV bevacizumabAnti-VEGFWhen Direct Oral Anticoagulants Should Not Be Standard Treatment JACC State-of-the-Art Review
Bejjani A, Khairani C, Assi A, Piazza G, Sadeghipour P, Talasaz A, Fanikos J, Connors J, Siegal D, Barnes G, Martin K, Angiolillo D, Kleindorfer D, Monreal M, Jimenez D, Middeldorp S, Elkind M, Ruff C, Goldhaber S, Krumholz H, Mehran R, Cushman M, Eikelboom J, Lip G, Weitz J, Lopes R, Bikdeli B. When Direct Oral Anticoagulants Should Not Be Standard Treatment JACC State-of-the-Art Review. Journal Of The American College Of Cardiology 2024, 83: 444-465. PMID: 38233019, DOI: 10.1016/j.jacc.2023.10.038.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsStandard of careRandomized controlled trialsOral anticoagulantsAtrial fibrillationCatheter-associated deep vein thrombosisCerebral venous sinus thrombosisControlled trialsVitamin K antagonistsThrombotic antiphospholipid syndromeEnd-stage renal diseaseLeft ventricular thrombusVenous thromboembolism treatmentVenous sinus thrombosisDeep vein thrombosisRheumatic heart diseaseReview of randomized controlled trialsEvidence-based reviewK antagonistsAntiphospholipid syndromeSinus thrombosisVentricular thrombusVein thrombosisThromboembolism treatmentVenous thrombosis
2008
Influence of Patients’ Socioeconomic Status on Clinical Management Decisions: A Qualitative Study
Bernheim SM, Ross JS, Krumholz HM, Bradley EH. Influence of Patients’ Socioeconomic Status on Clinical Management Decisions: A Qualitative Study. The Annals Of Family Medicine 2008, 6: 53-59. PMID: 18195315, PMCID: PMC2203396, DOI: 10.1370/afm.749.Peer-Reviewed Original ResearchConceptsClinical management decisionsPatients' socioeconomic statusClinical managementSocioeconomic statusPatient sPatient outcomesPrimary care physiciansStandard of careInfluence of patientLow socioeconomic statusVaried practice settingsHealth care qualitySES influencesCare physiciansHispanic ethnicityPhysician perspectivesPractice settingsCare qualityPatientsPhysiciansPatient interestMinority racial backgroundsInterview guideFinancial strainOutcomes
1999
Quality of care for patients hospitalized with heart failure at academic medical centers
Nohria A, Chen Y, Morton D, Walsh R, Vlasses P, Krumholz H. Quality of care for patients hospitalized with heart failure at academic medical centers. American Heart Journal 1999, 137: 1028-1034. PMID: 10347327, DOI: 10.1016/s0002-8703(99)70358-3.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionCongestive heart failureAcademic medical centerTime of dischargeStandard of careMedical CenterHeart failureACE inhibitorsAssessment of LVEFDiagnosis of CHFDaily weightEnzyme inhibitor therapyRetrospective chart reviewVentricular ejection fractionLarge clinical trialsPatient education guidelinesQuality of careHealth care policyChart reviewDietary counselingHospital dischargeEjection fractionInhibitor therapyTreatment guidelinesMedication compliance